================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               -------------------

                                    FORM 10-Q

[X]      QUARTERLY  REPORT  PURSUANT  TO SECTION  13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

                 For the Fiscal Quarter Ended September 30, 1999

[ ]      TRANSITION  REPORT  PURSUANT  TO SECTION 13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

               For the Transition period from _____ to _________.



                         Commission file number: 0-27596


                                 CONCEPTUS, INC.
             (Exact name of Registrant as specified in its charter)



            Delaware                                        94-3170244
(State or other jurisdiction of                          (I.R.S. Employer
 incorporation or organization)                         Identification No.)

                               1021 Howard Avenue
                              San Carlos, CA 94070
                    (Address of principal executive offices)

       Registrant's telephone number, including area code: (650) 802-7240

                               -------------------


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for at least the past 90 days.

         Yes     X                               No
                ---                                    ---

         As of September 30, 1999,  9,629,150 shares of the Registrant's  Common
Stock were outstanding.

================================================================================

<PAGE>

                                 CONCEPTUS, INC.

               FORM 10-Q For the Quarter Ended September 30, 1999

                                                       INDEX

                                                                            Page

               Facing sheet                                                   1

               Index                                                          2

Part I.        Financial Information

Item 1.        Financial Statements (Unaudited)

               a)   Consolidated  balance sheets at September 30, 1999
                    and December 31, 1998                                     3

               c)   Consolidated  statements  of  operations  for  the
                    three and nine month periods  ended  September 30,
                    1999 and September 30, 1998                               4

               c)   Consolidated statements of cash flows for the nine
                    month  periods   ended   September  30,  1999  and
                    September 30, 1998                                        5

               d)   Notes to consolidated financial statements                6

Item 2.        Management's Discussion and Analysis of Financial Condition
               and Results of Operations                                      6

Item 3.        Quantitative and Qualitative Disclosures About Market
               Risk                                                          11

Part II.       Other Information                                             12

               Signature                                                     13

               Index to Exhibits                                             14


                                       2
<PAGE>

                          PART I: FINANCIAL INFORMATION

ITEM 1.  Financial Statements
<TABLE>
                                           Conceptus, Inc.

                                     Consolidated Balance Sheets
                         (In thousands, except share and per share amounts)

<CAPTION>
                                                                September 30, 1999   December 31, 1998
                                                                    --------              --------
Assets                                                             (Unaudited)            (Note 1)
<S>                                                                 <C>                   <C>
  Current assets:
    Cash and cash equivalents                                       $  9,919              $ 11,503
    Short-term investments                                             2,767                 5,568
    Accounts receivable, net                                              19                   139
    Notes receivable                                                     195                  --
    Other current assets                                                 172                    65
                                                                    --------              --------

  Total current assets                                                13,072                17,275

  Property and equipment, net                                            935                 1,391

  Other assets                                                           305                   365
                                                                    --------              --------

                                                                    $ 14,312              $ 19,031
                                                                    ========              ========

Liabilities and stockholders' equity Current liabilities:
    Accounts payable                                                $    234              $    165
    Accrued compensation                                                 211                   421
    Accrued clinical costs                                               148                  --
    Other accrued liabilities                                            113                    92
    Current portion of deferred revenue                                   97                    97
                                                                    --------              --------

  Total current liabilities                                              803                   775

  Long-term portion of deferred revenue                                  162                   242

  Stockholders' equity:
    Common stock, $0.003 par value, 30,000,000 shares authorized,     63,573                63,570
      9,629,150 and 9,620,205 shares issued and outstanding at
        September 30, 1999 and December 31, 1998, respectively
    Stockholder notes receivable                                         (54)                  (54)
    Deferred compensation                                                (39)                 (106)
    Accumulated deficit                                              (50,133)              (45,396)
                                                                    --------              --------

  Total stockholders' equity                                          13,347                18,014
                                                                    --------              --------

                                                                    $ 14,312              $ 19,031
                                                                    ========              ========

<FN>
                           See notes to consolidated financial statements.
</FN>
</TABLE>

                                                 3
<PAGE>


                                 Conceptus, Inc.

                      Consolidated Statements of Operations
                                   (unaudited)
                    (In thousands, except per share amounts)

                                       Three Months Ended    Nine Months Ended
                                          September 30,         September 30,
                                       ------------------    ------------------
                                         1999      1998       1999       1998
                                       -------    -------    -------    -------
Net sales                              $    14    $    86    $    82    $   338
Cost of sales                               28         75        111      1,587
                                       -------    -------    -------    -------

Gross profit (loss)                        (14)        11        (29)    (1,249)

Operating expenses:
  Research and development               1,204        898      2,955      3,847
  Selling, general and administrative    1,135        731      2,399      4,550
                                       -------    -------    -------    -------

Total operating expenses                 2,339      1,629      5,354      8,397
                                       -------    -------    -------    -------

Operating loss                          (2,353)    (1,618)    (5,383)    (9,646)

Interest and investment income, net        197        287        646        997
                                       -------    -------    -------    -------

Net loss                               $(2,156)   $(1,331)   $(4,737)   $(8,649)
                                       =======    =======    =======    =======

Basic and diluted net loss per share   $ (0.22)   $ (0.14)   $ (0.49)   $ (0.91)
                                       =======    =======    =======    =======

Shares used in computing basic
  and diluted net loss per share         9,629      9,611      9,625      9,543
                                       =======    =======    =======    =======

                 See notes to consolidated financial statements.

                                       4
<PAGE>

                      Consolidated Statements of Cash Flows
                                   (Unaudited)
                Increase (Decrease) in Cash and Cash Equivalents
                                 (In thousands)

                                                             Nine Months Ended
                                                               September 30,
                                                           --------------------
                                                             1999        1998
                                                           --------    --------
Cash flows used in operating activities
Net loss                                                   $ (4,737)   $ (8,649)

Adjustments to reconcile net loss to net
     cash from (used  in) operating activities:
        Depreciation and amortization                           471         430
        Amortization of deferred compensation                    67          72
        Recognition of deferred revenue                         (80)        (73)
        Changes in operating assets and liabilities:
             Accounts receivable                                120         450
             Note receivable                                   (195)       (256)
             Inventory                                         --           355
             Other current assets                              (107)         89
             Accounts payable                                    69        (486)
             Accrued compensation                              (210)        139
             Accrued clinical costs                             148        --
             Other accrued liabilities                           21         (52)
                                                           --------    --------

Net cash used in operating activities                        (4,433)     (7,981)
                                                           --------    --------

Cash flows provided by investing activities
Purchase of investments                                        --       (19,034)
Maturities of investments                                     2,801      32,339
Capital expenditures                                            (15)       (826)
Change in other assets                                           60          13
                                                           --------    --------

Net cash provided by investing activities                     2,846      12,492
                                                           --------    --------

Cash flows provided by financing activities
Proceeds from issuance of common stock                            3          71
Principal payments on debt and capital obligations             --           (31)
                                                           --------    --------

Net cash provided by financing activities                         3          40
                                                           --------    --------

Net change in cash and cash equivalents                      (1,584)      4,551
Cash and cash equivalents at beginning of period             11,503       9,250
                                                           --------    --------
Cash and cash equivalents at end of period                 $  9,919    $ 13,801
                                                           ========    ========


                 See notes to consolidated financial statements.


                                       5
<PAGE>

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                    Unaudited

Note 1.  Summary of Significant Accounting Policies

Method of Preparation

         The  accompanying  consolidated  balance sheet as of September 30, 1999
and the  consolidated  statements of operations and cash flows for the three and
nine month  periods  ended  September  30,  1999 and 1998 have been  prepared by
Conceptus, Inc. ("Conceptus" or the "Company"), without audit. In the opinion of
management,  all adjustments,  consisting only of normal recurring  adjustments,
necessary to present fairly the financial position,  results of operations,  and
cash flows at September 30, 1999, and for all periods presented, have been made.
The  balance  sheet  as of  December  31,  1998 has been  derived  from  audited
financial statements as of that date.

         Although  the  Company   believes   that  the   disclosures   in  these
consolidated financial statements are adequate to make the information presented
not  misleading,  certain  information  and  footnote  disclosures  required  by
Generally Accepted Accounting  Principles for complete financial statements have
been  omitted  pursuant  to the  rules and  regulations  of the  Securities  and
Exchange  Commission  ("SEC").   This  financial  data  should  be  reviewed  in
conjunction with the audited financial  statements and notes thereto included in
the  Company's  Form 10-K for the year ended  December 31, 1998.  The results of
operations  for the three  and nine  months  ended  September  30,  1999 may not
necessarily  be  indicative  of the  operating  results for the full 1999 fiscal
year.

Computation of Net Loss Per Share

         Basic  earnings per share is computed using net income and the weighted
average number of common shares outstanding during the period.  Diluted earnings
per share is computed using net income and the weighted average number of common
and dilutive common equivalent shares outstanding during each period.  Under the
requirements for calculating basic earnings per share, the effect of potentially
dilutive  securities  such as stock  options is excluded.  Basic and diluted net
loss is computed  using the  weighted  average  number of shares of common stock
outstanding.

Comprehensive Income

         During the first three quarters of 1999 and 1998,  total  comprehensive
income (loss) was the same as net income  (loss) as unrealized  gains and losses
were immaterial.


Item 2. Management's  Discussion and Analysis of Financial Condition and Results
        of Operations

         The  following  discussion  should  be read  in  conjunction  with  the
unaudited  financial  statements and notes thereto  included in Part I-Item 1 of
this  Quarterly  Report.  In  addition,  except  for the  historical  statements
contained therein, the following discussion contains forward-looking  statements
within the meaning of Section 21E of the  Securities  Exchange  Act of 1934,  as
amended.  The Company  wishes to alert readers that the factors set forth in the
Company's  Annual  Report on Form 10-K for the year ended  December 31, 1998, as
well as other  factors,  including  those set forth in the following  discussion
could in the future affect, and in the past have affected,  the Company's actual
results  and could  cause the  Company's  results  for future  periods to differ
materially from those expressed in any forward-looking  statements made by or on
behalf of the Company.


                                       6
<PAGE>

Overview

         Since  inception on September 18, 1992,  Conceptus  has been  primarily
engaged in the design,  development  and marketing of innovative  interventional
medical devices for use in reproductive medicine. The Company's current focus is
to develop the STOP(TM) non-surgical permanent contraception device. STOP(TM) is
designed  to provide a less  invasive  alternative  to the most  common  form of
contraception  worldwide,  surgical  tubal  sterilization.  Data from the United
Nations estimate that 30% of worldwide  reproductive couples using contraception
rely on surgical  tubal  sterilization.  A survey  performed  by the Centers for
Disease Control,  indicates that surgical tubal  sterilization is the number one
form of contraception  in the United States,  and 35% of women aged 35 - 44 have
had a surgical tubal sterilization.

         The Company has a limited  history of  operations  and has  experienced
significant  operating losses since inception.  Operating losses are expected to
continue for at least the next several years as the Company  continues to expend
substantial  resources  to fund  clinical  trials in support of  regulatory  and
reimbursement approvals and to conduct research and product development.

         The  Company  continues  to progress in its  development  and  clinical
efforts of the  STOP(TM)  non-surgical  permanent  contraceptive  device.  As of
October  31,  1999,  there were 113 women with a history  of  fertility  who had
undergone  the STOP device  placement  procedure.  The  protocol  requires  that
patients  remain on  alternative  contraception  for three  months  after device
placement.  Fifty-six  of these women have  completed  the  three-month  waiting
period and are currently relying on STOP(TM) for contraception.  This represents
an accumulation of 226  woman-months of reliance on STOP(TM) and there have been
no reported pregnancies.  Conceptus's  bio-statisticians report that if STOP(TM)
had no contraceptive  effect,  the expected number of pregnancies among these 56
women  relying on  STOP(TM)  is 12, and that it is  extremely  unlikely  to have
observed zero  pregnancies  among these women. A large pivotal  trial,  however,
will be required to support a claim of permanent contraception.

         Device  related  adverse events have been reported in five women in the
Phase II study. All events involved  improper device placement and the resulting
inability to rely on the STOP(TM) devices for contraception.  Two of these women
elected to have a laparoscopic sterilization and STOP(TM) devices were retrieved
from the peritoneal cavity in these women without incident.  Conceptus  believes
these types of adverse events can be reduced to an  insignificant  level through
physician training, revision of the clinical protocol, and design evolution.

         STOP(TM)  is  designed  to  be  a  non-surgical  alternative  to  tubal
sterilization  that  can be  performed  in an  office  setting  without  general
anesthesia and with minimal patient discomfort. To support the feasibility of an
office  based  placement,  Conceptus  is  collecting  data in its Phase II trial
regarding  the time  required to complete  the  procedure,  the use of analgesia
and/or anesthesia,  patient tolerance of the procedure, and patient tolerance to
wearing  the  devices.  In the  Phase II  study,  94% of  procedures  have  been
performed without general  anesthesia and patient tolerance of the procedure has
been rated "good to excellent" in 91% of the cases.  The average  procedure time
has been 22 minutes. Patient tolerance to wearing the device has been rated very
good to excellent in 100% of patients at the scheduled follow-up visits.

                                       7
<PAGE>

         In summary,  data from the Phase II study  suggest  that  STOP(TM)  may
provide a unique value  proposition to the patient,  physician,  and payor.  The
popularity of surgical tubal sterilization underscores the importance that women
ascribe to taking control of their reproductive capability. STOP(TM) is designed
to provide  that same  control  while  eliminating  the most  significant  risks
associated with surgical tubal  sterilization,  which include the inherent risks
of incisional  surgery,  and the side-effects  and lengthy recovery  required by
general  anesthesia.   Because  tubal  sterilization  is  an  invasive  surgical
procedure,  at least 90% of these  procedures  are  performed  in a hospital  or
surgi-center under general  anesthesia.  Typical procedure time is about 30 - 45
minutes and is followed  by 3 - 4 hours of  hospital  or  surgi-center  recovery
time.  Additionally,  women  typically  take 2 - 3 days off from work after this
invasive procedure.  Data from the Phase II study suggests that STOP(TM) may cut
procedure time by about half,  eliminate a  recovery-room  stay  associated with
general  anesthesia,   and  speed  the  patient's  return  to  work  and  family
responsibilities.

         In  addition  to the  Company's  on-going  Phase II study,  the Company
continues to perform pre-hysterectomy studies to support the Company's theorized
mechanism of  contraception  of the STOP(TM)  device.  The Company  believes the
contraceptive effect of the STOP(TM) device is a result of a local benign tissue
response to the device  which  mechanically  alters the tubal  architecture  and
interferes with the function of the normal fallopian tube. Histological analysis
has been  performed on fallopian  tubes in which the STOP(TM)  device was placed
for an average of nine weeks  prior to  removal  of the  uterus.  This  analysis
demonstrated  that the STOP(TM) device had become  completely  incorporated into
the fallopian  tube tissue with a  proliferation  of fibrotic  tissue and smooth
muscle  cells  within the device.  Additionally,  the  response  was noted to be
localized to the device with no reaction beyond the STOP(TM) device.

         Based on the Phase II clinical  data the Company plans to actively seek
approval  from the Food & Drug  Administration  and other  regulatory  bodies to
commence an  international  Phase III clinical  trial in the first half of 2000.
The Company  plans to have trial sites in the U.S.,  Australia,  and Europe.  In
pursuit of  completion  of Phase II and Phase III clinical  trials,  the Company
plans  to  increase  the  level  of  expenditures  on  regulatory  and  clinical
activities,  manufaturing and quality  assurance of clinical trial product,  and
administrative support. The Company believes it has sufficient capital resources
to complete  enrollment in the pivotal trial,  but will need to raise additional
funding to prepare  and execute a market  release of the  STOP(TM)  device.  The
failure  to  secure  necessary  regulatory  approvals,  the  failure  to  secure
appropriate  distribution,  or the  failure to secure  additional  funding  will
materially and adversely affect the Company.  There can be no assurance that the
Company will be successful in these efforts.

         In  July  1998,  the  Company  effected  a  major  restructuring  which
eliminated all sales and marketing personnel,  the manufacturing  function,  and
significantly   reduced   administrative   overhead.   As  a   result   of  this
restructuring,  the Company  continues to seek sales and  marketing  partners to
distribute its current products,  the ERA and FUTURA Resectoscope  Sleeves,  the
STARRT Falloposcopy  system, and T-TAC products.  While the Company is committed
to establishing  an effective  distribution  channel for its existing  products,
there can be no  assurance  that the Company will be  successful  in doing so as
there is no proven distribution  channel for marketing the Company's products in
the United States or internationally.

                                       8
<PAGE>

         Future  revenues and results of operations may fluctuate  significantly
from quarter to quarter and will depend upon,  among other factors,  the ability
to attract marketing  partners and out-source  manufacturing,  the rate at which
the Company establishes its domestic and international distribution network, the
timing and size of  distributor  purchases,  actions  relating to regulatory and
reimbursement  matters,  the extent to which the Company's  products gain market
acceptance, the progress of clinical trials, and the introduction of competitive
products for diagnosis and treatment of the female reproductive system.


Results of Operations - Three and Nine Months Ended September 30, 1999 and 1998

         Sales  decreased  to $14,000  and $82,000 for the three and nine months
ended September 30, 1999,  respectively,  from $86,000 and $338,000 for the same
periods  in the  prior  year.  The  84%  and 76%  decreases,  respectively,  are
primarily due to lower unit  shipments of the Company's  T-TAC and ERA products.
The Company expects to continue its focus on the research and development  phase
and  therefore  expects that  revenues  will continue to decrease for the fourth
quarter of 1999.  Domestic sales  comprised 100% of sales for the three and nine
month periods ended September 30, 1999, respectively,  compared with 96% and 77%
in the prior year periods.

         Cost of sales  decreased to $28,000 and $111,000 for the three and nine
months ended September 30, 1999,  respectively,  from $75,000 and $1,587,000 for
the same periods in the prior year.  The 63% and 93%  decreases in cost of sales
for the three and nine months ended September 30, 1999,  respectively are due to
the elimination of manufacturing  operations  combined with lower unit shipments
of the Company's T-TAC and ERA products.

         Research and development  ("R&D") expenses,  which include clinical and
regulatory expenses for the three months ended September 30, 1999,  increased to
$1,204,000 from $898,000 for the same period in the prior year. The expenses for
the nine months ended September 30, 1999 decreased to $2,955,000 from $3,847,000
for the same period in the prior year.  The 34%  increase  for the three  months
ended  September 30, 1999 is  attributable  to the  increased  Phase II clinical
trials,  on-going  pre-hysterectomy  studies,  and  development  of an ergonomic
delivery  system.  The 23% decrease for the nine months ended September 30, 1999
is primarily  due to a reduced level of research and  development  activities on
the Company's STARRT and ERA product lines.

         Selling,  general and  administrative  ("SG&A")  expenses  increased to
$1,135,000  from $731,000 for the three months ended September 30, 1999. The 55%
increase in SG&A  expenses in the third  quarter is  attributable  primarily  to
$53,000 in legal  defense  costs  related to a sexual  harrassment  lawsuit  and
$655,000 of consulting  expenses to evaluate strategic options.  Excluding these
nonrecurring expenses, the SG&A expenses were $427,000 for the quarter. The SG&A
expenses for the nine months ended  September  30, 1999  decreased to $2,399,000
from  $4,550,000  for the same  period in the prior  year.  The 47%  decrease in
expenses for the nine months ended  September 30, 1999 is due to the elimination
of the sales and marketing force to focus on the STOP(TM) device.

         Net interest and  investment  income  decreased to $197,000 and $646,00
for the three and nine months  ended  September  30,  1999,  respectively,  from
$287,000 and $997,000 for the same periods in the prior year.  The decreases for
the three and nine months ended September 30, 1999 are a result of lower average
cash balances due to the  utilization of cash for operations.  Interest  expense
for the three and

                                       9
<PAGE>

nine months  ended  September  30,  1999 and the amount for the same  respective
periods in the prior year are immaterial.

         As a  result  of the  items  discussed  above,  net loss  increased  to
$2,156,000  from  $1,331,000  for the three months ended  September 30, 1999 and
decreased to $4,737,000  from $8,649,000 for the nine months ended September 30,
1999.

         The Company has a limited history of operations. Since its inception in
September  1992,  the  Company  has  been  engaged  primarily  in  research  and
development  of its T-TAC  and  STARRT  Falloposcopy  systems  and its  STOP(TM)
device,  and since  1996,  the ERA and FUTURA  product  lines.  The  Company has
generated   only  limited   revenues  and  has  only   limited   experience   in
manufacturing,  marketing or selling its products in commercial quantities.  The
Company has experienced  significant operating losses since inception and, as of
September  30, 1999,  had an  accumulated  deficit of $50  million.  The Company
expects its operating  losses to continue for at least the next several years as
it continues to expend substantial resources in research and product development
and  funding  clinical  trials in support  of its  STOP(TM)  device.  Due to the
expense and unpredictable nature of these activities,  there can be no assurance
that the Company will achieve or sustain profitability in the future.


Liquidity and Capital Resources

         At  September  30,  1999,  Conceptus  had cash,  cash  equivalents  and
investments of $12.7 million,  compared with $17.1 million at December 31, 1998.
The  decrease is primarily  due to $4.4  million  used in operating  activities.
Capital  expenditures  for the first nine  months of 1999  decreased  to $15,000
compared with capital expenditures of $826,000 in the prior year period. Capital
expenditures  in the  first  nine  months  of 1999  represent  the  purchase  of
additional  computer  equipment  required for research and development,  whereas
capital expenditures in the first half of 1998 represent leasehold improvements,
furniture  and  equipment  for a new  facility  which has been leased to a third
party through 2003.

         Conceptus   believes  that  its  existing  capital  resources  will  be
sufficient to fund its operations  through 2000.  However,  the Company's future
liquidity and capital requirements will depend upon numerous factors,  including
the  progress  of  the  Company's  clinical  research  and  product  development
programs,  the receipt of and the time required to obtain regulatory  clearances
and approvals,  and the resources  devoted to developing the Company's  STOP(TM)
product.  Accordingly,  there  can be no  assurance  that the  Company  will not
require additional  financing within this time frame and, therefore,  may in the
future seek to raise additional  funds through bank  facilities,  debt or equity
offerings  or other  sources of  capital.  Furthermore,  any  additional  equity
financing may be dilutive to stockholders, and debt financing, if available, may
involve  restrictive  convenants.  Additional  funding may not be available when
needed or on terms  acceptable  to the  Company,  which  would  have a  material
adverse effect on the Company.

         The "Year 2000 issue" arises because most computer systems and programs
were  designed to handle only a two-digit  year,  not a four-digit  year.  These
computer  systems and  programs  may  interpret  "00" as the year 1900 and could
either  stop  processing   date-related   computations  or  could  process  them
incorrectly in the year 2000.  The Company has been informed by its  information
system  vendors that such  systems are able to process the year 2000  accurately
and  accordingly  does  not  anticipate  any  Year  2000  issues  from  its  own
information  systems,  databases  or  programs.  However,  the Company  could be
adversely impacted by Year 2000 issues faced by major  distributors,  suppliers,
customers,  vendors and financial service  organizations  with which the Company

                                       10
<PAGE>

interacts.  The Company is in the process of  developing a plan to determine the
impact  that third  parties  which are not Year 2000  compliant  may have on the
operations of the Company. There can be no assurance that such plan will be able
to address  fully,  or at all, the impact of the Year 2000 issue on the Company,
which  could  have a  material  adverse  effect  upon  the  Company's  business,
financial condition and results of operations.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

         Not applicable.


                                       11
<PAGE>

                           Part II. Other Information



Item 1.  Legal Proceedings

         There are no material pending or threatened legal  proceedings  against
the Company.  The Company from time to time is involved in routine legal matters
incident to its  business.  While  management  currently  believes the amount of
ultimate  liability,  if any, with respect to these actions will not  materially
affect the  financial  position,  results of  operations,  or  liquidity  of the
Company, the ultimate outcome of any litigation is uncertain.


Item 2.  Changes in Securities

         None.

Item 3.  Defaults in Senior Securities

         None.

Item 4.  Submission of Matters to a Vote of Security Holders

         None.

Item 5.  Other Information

         None.

Item 6.  Exhibits and Reports on Form 8-K

(a)      Exhibit 27

                  Exhibit 27        Financial Data Schedule

(a)      Reports on Form 8-K.

                  None.




                                       12
<PAGE>

                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                 CONCEPTUS, INC.


                                By: /s/            OLIVER BROUSE
                                    --------------------------------------------
                                                   Oliver Brouse
                                                 Director of Finance
                                    (Duly Authorized and Principal Financial and
                                                 Accounting Director)


Date:    November 15, 1999


                                       13
<PAGE>

                                INDEX TO EXHIBITS


       Exhibit
        Number                    Description
        ------                    -----------

         27                 Financial Data Schedule




                                       14